Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer.

ABSTRACT: Apolipoprotein B mRNA editing enzyme catalytic polypeptide 3B (APOBEC3B) plays an important role in tumor mutagenesis. However, its clinical significance in gastric cancer (GC) remains largely unknown. We enrolled a total of 482 GC patients from Zhongshan Hospital, Fudan University for immunohistochemistry (IHC) staining to evaluate the prognostic and predictive values of APOBEC3B. Genomic and phenotypic datasets from the Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) cohort were downloaded for external validation and complementary bioinformatic analysis. Fresh specimens of additional 60 patients from Zhongshan Hospital, Fudan University were collected to detect CD8⁺ T cell phenotype with flow cytometry (FCM). The high expression of APOBEC3B indicated inferior

SUBMITTER: Xia S 

PROVIDER: S-EPMC8451457 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature